Member Highlights - Biweekly newsletter of the International Cytokine & Interferon Society

Member Highlight: Meet Yanick Crow, M.D., Ph.D.

February 17, 2025

The following interview was conducted by Signals+ Editor Maialen Sebastian-delaCruz, Ph.D. Connect with her on LinkedIn. The best life/career advice I have ever received was, “The harder you work, the luckier you get.” In the Crow Lab, we are interested in human monogenic diseases associated with chronically enhanced production of type I interferons [READ MORE]

Member Highlight: Meet Yanick Crow, M.D., Ph.D.

February 17, 2025

Headshots of Chris Hunter and Warren Leonard

Past-Presidents Dr Christopher A Hunter and Dr Warren J Leonard named AAI Distinguished Fellows

February 17, 2025

Congratulations Chris Hunter and Warren Leonard! Dr Christopher A Hunter and Dr Warren J Leonard were selected as Distinguished Fellows of the American Association of Immunologists (AAI) in this year’s class. Dr Hunter and Dr Leonard are Past-Presidents of International Cytokine and Interferon Society (ICIS) and of the International Cytokine [READ MORE]

Graphical abstract and citation of recent article from lab of Dr. Edward Chuong

“Regulation of human interferon signaling by transposon exonization” published in Cell

February 3, 2025

The following interview was conducted by Signals+ Editor Maialen Sebastian-delaCruz, Ph.D. Connect with her on LinkedIn. A recent study by Pasquesi et al from the Chuong lab published in Cell, “Regulation of human interferon signaling by transposon exonization” showed that transposable element exonization can yield functional protein isoforms as seen for [READ MORE]

Elias A. Said, Ph.D., Associate Professor, Sultan Qaboos University, Muscat, Oman

Member Highlight: Meet Elias Said

February 3, 2025

The following interview was conducted by Signals+ Editor Maialen Sebastian-delaCruz, Ph.D. Connect with her on LinkedIn. I am a researcher in the Immunology field, specifically innate immunity and cytokines. Also, an Associate Editor for scientific journals. My research has led to significant achievements, such as identifying the role of PD-1 in [READ MORE]

Single-arm, Dose-escalation Trial of Long-acting Recombinant Human IL-7 (NT-I7, Efineptakin Alfa) for Idiopathic CD4 Lymphopenia

February 3, 2025

ClinicalTrials.gov ID NCT05600920 Sponsor National Institute of Allergy and Infectious Diseases (NIAID) Information provided by National Institutes of Health Clinical Center (CC) (National Institute of Allergy and Infectious Diseases (NIAID)) Study Overview Brief Summary Background: Idiopathic CD4 lymphopenia (ICL) is a syndrome characterized by low levels of certain immune cells [READ MORE]

Share this: